We believe one of the main reasons for the devaluation of Probiodrug’s shares over the past year was the largely disappointing industry newsflow frustrating research on Abeta theory, even though Probiodrug’s technology is differentiated from all other Abeta therapies studied in late-stage trials. The recent surprise announcement of disease-modifying effect obtained by Biogen/Eisai with their MAb BAN2401 in a Phase II trial may reignite interest in the amyloid theory and in the Alz
01 Nov 2018
Probiodrug - Support for Abeta theory from Biogen/Eisai
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Probiodrug - Support for Abeta theory from Biogen/Eisai
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
01 Nov 2018 -
Author:
Dr Jonas Peciulis -
Pages:
13
We believe one of the main reasons for the devaluation of Probiodrug’s shares over the past year was the largely disappointing industry newsflow frustrating research on Abeta theory, even though Probiodrug’s technology is differentiated from all other Abeta therapies studied in late-stage trials. The recent surprise announcement of disease-modifying effect obtained by Biogen/Eisai with their MAb BAN2401 in a Phase II trial may reignite interest in the amyloid theory and in the Alz